ADVERSE REACTIONS
The following serious adverse reactions are discussed in greater detail in other sections of the label:
- Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism [see Warnings and Precautions]
- Increased mortality and/or increased risk of tumor progression or recurrence in Patients With Cancer [see Warnings and Precautions]
- Hypertension [see Warnings and Precautions]
- Seizures [see Warnings and Precautions]
- PRCA [see Warnings and Precautions]
- Serious allergic reactions [see Warnings and Precautions]
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
Patients with Chronic Kidney Disease
Adult Patients
Three double-blind, placebo-controlled studies, including 244 patients with CKD on dialysis, were used to identify the adverse reactions to PROCRIT. In these studies, the mean age of patients was 48 years (range: 20 to 80 years). One hundred and thirty-three (55%) patients were men. The racial distribution was as follows: 177 (73%) patients were white, 48 (20%) patients were black, 4 (2%) patients were Asian, 12 (5%) patients were other, and racial information was missing for 3 (1%) patients.
Two double-blind, placebo-controlled studies, including 210 patients with CKD not on dialysis, were used to identify the adverse reactions to PROCRIT. In these studies, the mean age of patients was 57 years (range: 24 to 79 years). One hundred and twenty-one (58%) patients were men. The racial distribution was as follows: 164 (78%) patients were white, 38 (18%) patients were black, 3 (1%) patients were Asian, 3 (1%) patients were other, and racial information was missing for 2 (1%) patients.
The adverse reactions with a reported incidence of ≥ 5% in PROCRIT-treated patients and that occurred at a ≥ 1% higher frequency than in placebo-treated patients are shown in the table below:
Table 3. Adverse Reactions in Patients With CKD on Dialysis
| Adverse Reaction |
PROCRIT-treated Patients
(n = 148) |
Placebo-treated Patients
(n = 96) |
| Hypertension |
27.7% |
12.5% |
| Arthralgia |
16.2% |
3.1% |
| Muscle spasm |
7.4% |
6.3% |
| Pyrexia |
10.1% |
8.3% |
| Dizziness |
9.5% |
8.3% |
| Medical Device Malfunction (artificial kidney clotting during dialysis) |
8.1% |
4.2% |
| Vascular Occlusion (vascular access thrombosis) |
8.1% |
2.1% |
| Upper respiratory tract infection |
6.8% |
5.2% |
An additional serious adverse reaction that occurred in less than 5% of epoetin alfa-treated dialysis patients and greater than placebo was thrombosis (2.7% PROCRIT and 1% placebo) [see Warnings and Precautions].
The adverse reactions with a reported incidence of ≥ 5% in PROCRIT-treated patients and that occurred at a ≥ 1% higher frequency than in placebo-treated patients are shown in the table below:
Table 4. Adverse Reactions in Patients With CKD Not on Dialysis
| Adverse Reactions |
PROCRIT-treated Patients
(n = 131) |
Placebo-treated Patients
(n = 79) |
| Hypertension |
13.7% |
10.1% |
| Arthralgia |
12.2% |
7.6% |
Additional serious adverse reactions that occurred in less than 5% of epoetin alfa-treated patients not on dialysis and greater than placebo were erythema (0.8% PROCRIT and 0% placebo) and myocardial infarction (0.8% PROCRIT and 0% placebo) [see Warnings and Precautions].
Pediatric Patients
In pediatric patients with CKD on dialysis, the pattern of adverse reactions was similar to that found in adults.
Zidovudine-treated HIV-infected Patients
A total of 297 zidovudine-treated HIV-infected patients were studied in 4 placebo-controlled studies. A total of 144 (48%) patients were randomly assigned to receive PROCRIT and 153 (52%) patients were randomly assigned to receive placebo. PROCRIT was administered at doses between 100 and 200 Units/kg 3 times weekly subcutaneously for up to 12 weeks.
For the combined PROCRIT treatment groups, a total of 141 (98%) men and 3 (2%) women between the ages of 24 and 64 years were enrolled. The racial distribution of the combined PROCRIT treatment groups was as follows: 129 (90%) white, 8 (6%) black, 1 (1%) Asian, and 6 (4%) other.
In double-blind, placebo-controlled studies of 3 months duration involving approximately 300 zidovudine-treated HIV-infected patients, adverse reactions with an incidence of ≥ 1% in patients treated with PROCRIT were:
Table 5. Adverse Reactions in Zidovudine-treated HIV-infected Patients
| Adverse Reaction |
PROCRIT
(n = 144) |
Placebo
(n = 153) |
| Pyrexia |
42% |
34% |
| Cough |
26% |
14% |
| Rash |
19% |
7% |
| Injection site irritation |
7% |
4% |
| Urticaria |
3% |
1% |
| Respiratory tract congestion |
1% |
Not reported |
| Pulmonary embolism |
1% |
Not reported |
Cancer Patients on Chemotherapy
The data below were obtained in Study C1, a 16-week, double-blind, placebo-controlled study that enrolled 344 patients with anemia secondary to chemotherapy. There were 333 patients who were evaluable for safety; 168 of 174 patients (97%) randomized to PROCRIT received at least 1 dose of study drug, and 165 of 170 patients (97%) randomized to placebo received at least 1 placebo dose. For the once weekly PROCRIT-treatment group, a total of 76 men (45%) and 92 women (55%) between the ages of 20 and 88 years were treated. The racial distribution of the PROCRIT-treatment group was 158 white (94%) and 10 black (6%). PROCRIT was administered once weekly for an average of 13 weeks at a dose of 20,000 to 60,000 IU subcutaneously (mean weekly dose was 49,000 IU).
The adverse reactions with a reported incidence of ≥ 5% in PROCRIT-treated patients that occurred at a higher frequency than in placebo-treated patients are shown in the table below:
Table 6. Adverse Reactions in Cancer Patients
| Adverse Reaction |
PROCRIT
(n = 168) |
Placebo
(n = 165) |
| Nausea |
35% |
30% |
| Vomiting |
20% |
16% |
| Myalgia |
10% |
5% |
| Arthralgia |
10% |
6% |
| Stomatitis |
10% |
8% |
| Cough |
9% |
7% |
| Weight decrease |
9% |
5% |
| Leukopenia |
8% |
7% |
| Bone pain |
7% |
4% |
| Rash |
7% |
5% |
| Hyperglycemia |
6% |
4% |
| Insomnia |
6% |
2% |
| Headache |
5% |
4% |
| Depression |
5% |
4% |
| Dysphagia |
5% |
2% |
| Hypokalemia |
5% |
3% |
| Thrombosis |
5% |
3% |
Surgery Patients
Four hundred sixty-one patients undergoing major orthopedic surgery were studied in a placebo-controlled study (S1) and a comparative dosing study (2 dosing regimens, S2). A total of 358 patients were randomly assigned to receive PROCRIT and 103 (22%) patients were randomly assigned to receive placebo. PROCRIT was administered daily at a dose of 100 to 300 IU/kg subcutaneously for 15 days or at 600 IU/kg once weekly for 4 weeks.
For the combined PROCRIT treatment groups, a total of 90 (25%) and 268 (75%) women between the ages of 29 and 89 years were enrolled. The racial distribution of the combined PROCRIT treatment groups was as follows: 288 (80%) white, 64 (18%) black, 1 (< 1%) Asian, and 5 (1%) other.
The adverse reactions with a reported incidence of ≥ 1% in PROCRIT-treated patients that occurred at a higher frequency than in placebo-treated patients are shown in the table below:
Table 7. Adverse Reactions in Surgery Patients
| Adverse Reaction |
Study S1 |
Study S2 |
PROCRIT
300 U/kg |
PROCRIT
100 U/kg |
Placebo |
PROCRIT
600 U/kg × 4 weeks |
PROCRIT
300 U/kg × 15 days |
| (n = 112)
|
(n = 101)
|
(n = 103)
|
(n = 73)
|
(n = 72)
|
| Nausea |
47% |
43% |
45% |
45% |
56% |
| Vomiting |
21% |
12% |
14% |
19% |
28% |
| Pruritus |
16% |
16% |
14% |
12% |
21% |
| Headache |
13% |
11% |
9% |
10% |
18% |
| Injection site pain |
13% |
9% |
8% |
12% |
11% |
| Chills |
7% |
4% |
1% |
1% |
0% |
| Deep vein thrombosis |
6% |
3% |
3% |
0%
|
0%
|
| Cough |
5% |
4% |
0% |
4% |
4% |
| Hypertension |
5% |
3% |
5% |
5% |
6% |
| Rash |
2% |
2% |
1% |
3% |
3% |
| Edema |
1% |
2% |
2% |
1% |
3% |
Postmarketing Experience
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been identified during postmarketing use of PROCRIT:
- Seizures [see Warnings and Precautions]
- PRCA [see Warnings and Precautions]
- Serious allergic reactions [see Warnings and Precautions]
- Injection site reactions, including irritation and pain
- Porphyria
Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity. Neutralizing antibodies to epoetin alfa that cross-react with endogenous erythropoietin and other ESAs can result in PRCA or severe anemia (with or without other cytopenias) [see Warnings and Precautions
].
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to PROCRIT with the incidence of antibodies to other products may be misleading.
|
